Eli Lilly and Company (NYSE:LLY) closed Friday at $1,208.12, up 7.13%, in a move that added approximately $75.7 billion to its market capitalization. The rally was fueled by positive European regulatory news for its blood cancer drug Jaypirca and growing anticipation of Medicare coverage for obesity treatments under the GLP-1 Bridge program, set to begin July 1.
The one-day surge in market value dwarfed Jaypirca's first-quarter sales of $165 million, representing a multiple of roughly 459 times. Nearly 7.73 million shares changed hands, about 2.5 times the average volume, underscoring intense investor interest.
Lilly announced that the European Medicines Agency's CHMP issued a positive opinion for Jaypirca in adults with chronic lymphocytic leukemia, regardless of prior BTK inhibitor therapy. The European Commission is expected to decide within one to two months. Simultaneously, the same data is under review by the U.S. FDA, with a decision anticipated in the second half of 2026.
Jacob Van Naarden, president of Lilly Oncology, described Jaypirca as a “meaningful new option.” Dr. Paolo Ghia of Università Vita-Salute San Raffaele highlighted the trial data’s “clinical value.” However, Jaypirca’s sales remain modest compared to Lilly’s blockbuster GLP-1 drugs: Mounjaro brought in $8.66 billion and Zepbound $4.16 billion in the same quarter, making the diabetes and obesity franchise roughly 78 times larger.
The stock’s valuation is driven by its GLP-1 platform potential rather than oncology alone. The upcoming Medicare GLP-1 Bridge, running from July 1 through December 31, 2027, will allow eligible Part D patients to access drugs like Foundayo or Zepbound for weight control at $50 per fill, subject to prior authorization. Lilly USA president Ilya Yuffa noted that about 20 million Medicare patients may meet clinical criteria for obesity drugs, calling treatment “within reach.” Dr. Rachel Batterham, head of global cardiometabolic health at Lilly, emphasized that obesity is a “chronic, complex disease.”
Healthcare stocks broadly rallied on Friday, with the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) climbing 2.7%, its best session since June 4. Lilly outperformed the sector, driven by the dual catalysts. According to WSJ data, the average analyst price target stands at $1,264.92, with a median of $1,280.50. At Friday’s close, Lilly trades about 4.5% below the average target and 5.7% below the median, suggesting further upside potential.
Looking ahead, market focus will be on the Medicare GLP-1 Bridge uptake after July 1. U.S. equity markets will be closed on Friday, July 3, for Independence Day. Lilly’s next earnings call is scheduled for August 5 at 10:00 a.m. EDT.
